Novo increases fatty liver efforts: "We've seen some highly convincing data"

Pharmaceutical company Novo Nordisk expands its emphasis on the fatty liver disease NASH. There's a huge market, but no one has solved the puzzle yet.

Novo Nordisk Executive Vice President, Development Martin Holst Lange | Photo: Novo Nordisk / PR

Danish pharmaceutical company Novo Nordisk keeps powering ahead in its efforts to find the first drug in the world which can treat the serious fatty liver disease non-alcoholic steatohepatitis (NASH).

"We've seen some highly convincing data with semaglutide alone. It's close to the best we've ever seen in the area. Our data is more robust from the fact that we included more patients, and included them for longer than what we've seen in many other studies," says Novo Nordisk Executive Vice President, Development Martin Holst Lange.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs